Lichen China Limited Class A Ordinary Shares (LICN)
Official siteINDUSTRIALS • SPECIALTY BUSINESS SERVICES • NASDAQ
Market Cap: $991,120
Last updated: Nov 17, 2026 at 11:06 AM ET
Lichen China Limited Class A Ordinary Shares (LICN) Financials: Revenue, Profit and Cash Flow
Lichen China Limited Class A Ordinary Shares reported revenue of $24.52M for the fiscal year ended Dec 31, 2025, down 40.9% from the year before. That year, net income was -$21.96M with a net margin of -89.6%, operating cash flow was -$17.85M and free cash flow was -$17.85M. The quarter ended Jun 30, 2026 had revenue of $10.26M and net income of -$11.55M.
Revenue and Margins
The operating margin was -58.8% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 10 years to Dec 2025, revenue grew from $14.76M, a compound annual rate of 5.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $24.52M | -40.9% | 37.3% | -58.8% | -89.6% |
| Dec 2024 | $41.48M | +4.3% | 61.9% | -11.0% | -14.8% |
| Dec 2023 | $39.76M | +17.6% | 61.2% | 30.8% | 21.0% |
| Dec 2022 | $33.80M | -1.4% | 59.7% | 31.5% | 23.1% |
| Dec 2021 | $34.30M | +11.8% | 59.7% | 32.9% | 24.7% |
| Dec 2020 | $30.67M | -3.0% | 61.4% | 28.7% | 20.9% |
| Dec 2019 | $31.60M | N/A | 61.2% | 30.8% | 22.4% |
| Dec 2017 | $25.58M | +23.1% | 71.3% | 36.4% | 25.4% |
| Dec 2016 | $20.78M | +40.8% | 73.0% | 41.5% | 28.0% |
| Dec 2015 | $14.76M | N/A | 71.3% | 36.5% | 26.8% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $24.52M | $41.48M | $39.76M | $33.80M | $34.30M | $30.67M | $31.60M | $25.58M | $20.78M | $14.76M |
| Cost of revenue | $15.38M | $15.80M | $15.44M | $13.61M | $13.82M | $11.83M | $12.26M | $7.35M | $5.61M | $4.23M |
| Gross profit | $9.14M | $25.67M | $24.32M | $20.19M | $20.48M | $18.84M | $19.34M | $18.24M | $15.17M | $10.53M |
| Research and development | $0 | $1.38M | $1.19M | $1.06M | $1.08M | $930.00K | $0 | $620.13K | $397.38K | $396.65K |
| Operating income | -$14.41M | -$4.55M | $12.26M | $10.65M | $11.30M | $8.79M | $9.73M | $9.30M | $8.63M | $5.39M |
| Net income | -$21.96M | -$6.14M | $8.34M | $7.82M | $8.46M | $6.41M | $7.07M | $6.51M | $5.82M | $3.96M |
| EBITDA | -$10.26M | -$1.68M | $15.18M | $13.33M | $13.74M | $10.95M | $11.97M | $9.82M | $8.96M | $5.62M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.26M | $10.26M | $14.26M | $23.38M | $18.10M | $23.83M | $11.92M | $15.93M | $17.66M | N/A | $8.83M | $16.15M |
| Gross profit | $1.55M | $2.54M | $6.59M | $14.71M | $10.96M | $14.49M | $7.25M | $9.83M | $9.79M | N/A | $4.89M | $10.40M |
| Operating income | -$8.72M | -$9.16M | -$5.25M | -$6.25M | $1.70M | $9.41M | $4.70M | $2.85M | $4.88M | N/A | $2.44M | $5.77M |
| Net income | -$11.55M | -$12.61M | -$9.36M | -$6.91M | $767.00K | $6.98M | $3.49M | $1.36M | $3.49M | N/A | $1.74M | $4.33M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $211.00K by $26.70M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $75.57M | $79.84M | $65.55M | $46.52M | $42.94M | $33.35M | $28.79M | $21.85M | $14.73M | $11.48M |
| Current assets | $36.17M | $34.01M | $40.13M | $27.27M | $23.89M | $11.65M | $7.42M | $10.84M | $12.62M | $10.70M |
| Cash and equivalents | $26.91M | $26.71M | $25.86M | $22.60M | $16.84M | $8.66M | $5.39M | $5.01M | $4.62M | $1.72M |
| Total liabilities | $5.02M | $4.28M | $4.13M | $5.42M | $6.11M | $5.71M | $5.07M | $3.28M | $3.82M | $3.09M |
| Short-term debt | $211.00K | $56.00K | $95.00K | $88.00K | $345.00K | $337.00K | $315.00K | N/A | N/A | N/A |
| Shareholder equity | $70.55M | $73.18M | $61.42M | $41.11M | $36.83M | $27.64M | $23.73M | $18.57M | $10.90M | $8.40M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $65.29M | $75.57M | $75.57M | $67.21M | $79.84M | $79.84M | $72.59M | $65.55M | $65.55M | $65.55M | $56.19M | $46.52M |
| Total liabilities | $4.42M | $5.02M | $5.02M | $2.96M | $4.28M | $4.28M | $2.81M | $4.13M | $4.13M | $4.13M | $2.92M | $5.42M |
| Cash and equivalents | $19.60M | $26.91M | $26.91M | $22.57M | $26.71M | $26.71M | $34.19M | $25.86M | $25.86M | $25.86M | $18.81M | $22.60M |
| Shareholder equity | $60.88M | $70.55M | $70.55M | $64.25M | $73.18M | $73.18M | $69.78M | $61.42M | $61.42M | $61.42M | $53.28M | $41.11M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2017 | Dec 2016 | Dec 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$17.85M | -$5.57M | $557.00K | $10.77M | $7.30M | $8.35M | $13.57M | $6.36M | $8.80M | $3.72M |
| Capital expenditures | $0 | $5.93M | $3.20M | $2.84M | $28.00K | $1.16M | $10.83M | $4.46M | $1.76M | $122.99K |
| Free cash flow | -$17.85M | -$11.51M | -$2.65M | $7.92M | $7.28M | $7.19M | $2.74M | $1.91M | $7.04M | $3.59M |
| Dividends paid | N/A | N/A | N/A | $0 | $0 | $4.35M | $7.25M | N/A | $3.01M | N/A |
| Investing cash flow | -$5.48M | -$9.89M | -$9.87M | -$2.84M | $561.00K | -$1.16M | -$10.83M | -$6.53M | -$2.96M | -$4.90M |
| Financing cash flow | $23.61M | $13.09M | $14.10M | -$327.00K | -$327.00K | -$4.35M | -$8.99M | $244.00K | -$2.66M | $2.30M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.81M | -$15.99M | -$1.85M | -$9.26M | $3.69M | $681.00K | N/A | $340.50K | -$124.00K | $5.58M | $2.79M |
| Capital expenditures | $5.81M | $0 | $0 | $36.00K | $0 | $2.29M | $0 | $1.15M | $5.51M | $1.92M | $959.50K |
| Free cash flow | -$11.62M | -$15.99M | -$1.85M | -$9.29M | $3.69M | -$1.61M | N/A | -$806.50K | -$5.63M | $3.66M | $1.83M |
Frequently Asked Questions About LICN
What is Lichen China Limited Class A Ordinary Shares' annual revenue?
Lichen China Limited Class A Ordinary Shares reported revenue of $24.52M for the fiscal year ended Dec 31, 2025.
How fast is Lichen China Limited Class A Ordinary Shares' revenue growing?
Revenue was down 40.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -10.2%.
Is Lichen China Limited Class A Ordinary Shares profitable?
No. Lichen China Limited Class A Ordinary Shares reported net income of -$21.96M for the fiscal year ended Dec 31, 2025, with a net margin of -89.6%.
How much free cash flow does LICN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$17.85M minus capital expenditures of $0 produced free cash flow of -$17.85M.
How much debt does Lichen China Limited Class A Ordinary Shares have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $211.00K and cash and equivalents of $26.91M.
LICN pages: Overview, Financials